Physicians and Patients Measure Different Dimension on Assessment for Gastroesophageal Reflux Disease-related Symptoms

Abstract

Background/AimsGastroesophageal reflux disease is a highly prevalent disease. Assessing treatment efficacy is critical in that clinical endpoints are properly evaluated. Clinical tools for symptoms severity assessment should be discriminative, predictive and evaluative.MethodsIn this study we compared a patient-oriented symptoms evaluation (ReQuest™) vs a structured interview assessment initiated by a physician (sickness impact profile [SIP]). Both questionnaires were analyzed in a multidimensional space using latent factors. Five dimensions were found: 1 for the short ReQuest™ questionnaire and 4 for SIP.ResultsWe included 1,522 women and 1,296 men; mean age was 36 ± 7 years, and mean body mass index was 26 ± 4. The score questionnaire assessment evaluation by physicians and patients did not correlate between them (between r = 0.03 and 0.26) except nausea and sleep disorder (r = 0.45 and 0.51) but both were sensitive enough to detect changes after treatment (P < 0.05). Medical specialty of the physician showed effect on the score of both, ReQuest™ and SIP evaluation. Questionnaire variance decomposition due to specialist was only 2% (P < 0.05).ConclusionsWhile both evaluations are orthogonal (non-correlated), meaning patients and physicians measured diverse aspects of the same disease, they both were able to measure patient's improvement with treatment.

Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket‐targeting alginate–antacid (Gaviscon Double Action) – a double‐blind, placebo‐controlled, pilot study in gastro‐oesophageal reflux disease

“…Symptom relief is the major goal of treatment in GERD. As such, patient questionnaires, such as the RDQ, are appropriate tools for therapeutic assessment, particularly since self‐reported symptom status is considered to be as reliable as physician assessment . The RDQ is a validated 12‐item questionnaire that allows assessment of the frequency and severity of both GERD and dyspeptic symptoms …”

Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group

“…Improvements were observed in a broad range of GERD-associated symptoms following 4 weeks of treatment with pantoprazole-Mg 40 mg once daily according to both, patient and physician assessments, although the two assessments did not correlate with each other 16. All symptoms were reduced by at least 80% from baseline according to physicians' assessments (Table 3).…”

Heritability and genetic correlation between GERD symptoms severity, metabolic syndrome, and inflammation markers in families living in Mexico City

“…This questionnaire was tried out in Germany, France, Spain, the United Kingdom, and the United States [30,31], and has been translated into different languages to be applied in various locations including Mexico [32,33]. In addition to this questionnaire, participants also filled out a questionnaire of socio-demographic characteristics.…”

“…Severity of GERD symptoms was assessed by the ReQuest in Practice questionnaire consisting of six dimensions (general well-being, acidity complaints, lower abdominal complaints, upper abdominal complaints, nausea, and sleep disturbances) using a visual analog scale of 10 cms, referring to the severity of these symptoms in the last 24 hours. This questionnaire was tried out in Germany, France, Spain, the United Kingdom, and the United States [ 30 , 31 ], and has been translated into different languages to be applied in various locations including Mexico [ 32 , 33 ]. In addition to this questionnaire, participants also filled out a questionnaire of socio-demographic characteristics.…”